Anixa Biosciences secures Korean patent for breast cancer vaccine

Anixa Biosciences has secured patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology. The patent expands Anixa’s IP portfolio beyond the US and existing international markets. The vaccine targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain types of breast cancer. Credit: NMK-Studio/Shutterstock.com. Anixa Biosciences has secured a patent from the Korean Ministry of Intellectual Property (MOIP) for its breast cancer vaccine technology. The MOIP has issued Patent Number 10-2960889, providing protection for Anixa’s breast cancer vaccine approach in South Korea through 2040. LOA and PTSR Model AE-37…

Source: Pharmaceutical Technology